VIOLIN: Vaccine Investigation and Online Information Network

Japanese encephalitis virus

Table of Contents

General Information
Vaccine Related Pathogen Genes
1. E protein from West Nile Virus (Other)
2. PrM from West Nile Virus (Other)
3. E (Protective antigen)
4. envelope (E) proteins (Protective antigen)
5. M protein (Protective antigen)
6. NS1 (Protective antigen)
7. NS1 (Protective antigen)
8. NS3 (Protective antigen)
9. NS5 (Protective antigen)
10. PreM (Protective antigen)
11. premembrane protein (Protective antigen)
12. PrM (Protective antigen)
Vaccine Related Host Genes
1. Ifng (Interferon gamma)
Vaccine Information
References

I. General Information

1. NCBI Taxonomy ID:

11072

2. Disease:

Japanese encephalitis

3. Introduction

Japanese encephalitis virus is a virus from the family Flaviviridae. It causes the mosquito-borne Japanese encephalitis. Japanese encephalitis is the leading cause of viral encephalitis in Asia, with 30,000–50,000 cases reported annually. Case-fatality rates range from 0.3% to 60% and depends on the population and on age. Rare outbreaks in U.S. territories in Western Pacific have occurred. This disease often occurs in rural areas but not usually in urban areas. Severe rigors, fever, headache and malaise are non-specific symptoms for the first week. Signs which develop during the acute encephalitic stage include neck rigidity, cachexia, hemiparesis, convulsions, and fever. Mental retardation developed from this disease usually leads to coma. Mortality of this disease varies but is generally much higher in children (Wiki: Japanese encephalitis).

4. Microbial Pathogenesis

Japanese encephalitis virus infects the lumen of the endoplasmic reticulum and rapidly accumulates substantial amounts of viral proteins.

5. Host Ranges and Animal Models

Domestic pigs and wild birds are reservoirs of the virus; transmission to humans may cause severe symptoms.

6. Host Protective Immunity

Infection with JEV confers life-long immunity (Wiki: Japanese encephalitis). For JE, both arms have been considered to be important for protection from the disease, since passive transfer of neutralizing antibodies or virus-specific T cells including CTLs can protect mice from a lethal challenge (Konishi et al., 2003).

II. Vaccine Related Pathogen Genes

1. E

Gene Name : E
Sequence Strain (Species/Organism) : Japanese encephalitis virus
VO ID : VO_0011145
NCBI Protein GI : 16445023
Other Database IDs : CDD:279241
CDD:213392
CDD:213897
Taxonomy ID : 11072
Gene Strand (Orientation) : ?
Protein Name : envelope protein
Protein pI : 7.88
Protein Weight : 49812.26
Protein Length : 577
Protein Note : Flavivirus glycoprotein, central and dimerization domains; pfam00869

Protein Sequence : Show Sequence

>AAK31640.1 envelope protein, partial [Japanese encephalitis virus]
FNCLGMGNRDFIEGASGATWVDLVLEGDSCLTIMANDKPTLDVRMINIEASQLAEVRSYCYHASVTDIST
VARCPTTGEAHNEKRADSSYVCKQGFTDRGWGNGCGLFGKGSIDTCAKFSCTSKAIGRTIQPENIKYKVG
IFVHGATTSENHGNYSAQVGASQAAKFTVTPNAPSITLKLGDYGEVTLDCEPRSGLNTEAFYVMTVGSKS
FLVHREWFHDLALPWTSPSSTAWRNRELLMEFEEAHATKQSVVALGSQEGGLHQALAGAIVVEYSSSVKL
TSGHLKCRLKMDKLALKGTTYGMCTEKFSFAKNPADTGHGTVVIELSYSGSDGPCKIPIVSVASLNDMTP
VGRLVTVNPFVATSSANSKVLVEMEPPFGDSYIVVGRGDKQINHHWHKAGSTLGKAFSTTLKGAQRLAAL
GDTAWDFGSIGGVFNSIGKAVHQVFGGAFRTLFGGMSWITQGLMGALLLWMGVNARDRSIALAFLATGGV
LVFLATNVHA

Molecule Role : Protective antigen
Molecule Role Annotation : Researchers constructed a recombinant pseudotype baculovirus encoding the JEV envelope (E) protein and demonstrated that it could elicit high protective immunity in mice. Intramuscular injections of BV-G-E at various doses into mice produced higher levels of JEV-specific neutralizing antibodies, IFN-gamma and better protective efficacy against a lethal challenge with JEV than that of pc-E. Furthermore, BV-G-E could elicit a higher level of cellular immunity response and provide equal protective efficacy against JEV challenge compared to inactivated vaccine (Li et al., 2009).
Related Vaccine(s): Japanese encephalitis virus DNA vaccine encoding E protein , Japanese encephalitis virus DNA Vaccine P-JEV , Japanese encephalitis virus DNA Vaccine pCJ-3/E encoding E , Japanese encephalitis virus vaccine BV-G-E , NYVAC-JEV- prM/E/ NS1

2. E protein from West Nile Virus

Gene Name : E protein from West Nile Virus
Sequence Strain (Species/Organism) : West Nile virus NY99
NCBI Gene ID : 5714902
NCBI Protein GI : 158516888
Locus Tag : WNVNY99_gp1
Genbank Accession : DQ211652
Protein Accession : YP_001527877
Taxonomy ID : 11082
Gene Starting Position : 96
Gene Ending Position : 10397
Gene Strand (Orientation) : +
Protein Name : polyprotein
Protein pI : 8.52
Protein Weight : 353459.58
Protein Length : 3433

DNA Sequence : Show Sequence

>gi|158516887:96-10397 West Nile virus, complete genome
GATGTCTAAGAAACCAGGAGGGCCCGGCAAGAGCCGGGCTGTCAATATGCTAAAACGCGGAATGCCCCGC
GTGTTGTCCTTGATTGGACTGAAGAGGGCTATGTTGAGCCTGATCGACGGCAAGGGGCCAATACGATTTG
TGTTGGCTCTCTTGGCGTTCTTCAGGTTCACAGCAATTGCTCCGACCCGAGCAGTGCTGGATCGATGGAG
AGGTGTGAACAAACAAACAGCGATGAAACACCTTCTGAGTTTTAAGAAGGAACTAGGGACCTTGACCAGT
GCTATCAATCGGCGGAGCTCAAAACAAAAGAAAAGAGGAGGAAAGACCGGAATTGCAGTCATGATTGGCC
TGATCGCCAGCGTAGGAGCAGTTACCCTCTCTAACTTCCAAGGGAAGGTGATGATGACGGTAAATGCTAC
TGACGTCACAGATGTCATCACGATTCCAACAGCTGCTGGAAAGAACCTATGCATTGTCAGAGCAATGGAT
GTGGGATACATGTGCGATGATACTATCACTTATGAATGCCCAGTACTGTCGGCTGGTAATGATCCAGAAG
ACATCGACTGTTGGTGCACAAAGTCAGCAGTCTACGTCAGGTATGGAAGATGCACCAAGACACGCCACTC
AAGACGCAGTCGGAGGTCACTGACAGTGCAGACACACGGAGAAAGCACTCTAGCGAACAAGAAGGGGGCT
TGGATGGACAGCACCAAGGCCACAAGGTATTTGGTAAAAACAGAATCATGGATCTTGAGGAACCCTGGAT
ATGCCCTGGTGGCAGCCGTCATTGGTTGGATGCTTGGGAGCAACACCATGCAGAGAGTTGTGTTTGTCGT
GCTATTGCTTTTGGTGGCCCCAGCTTACAGCTTCAACTGCCTTGGAATGAGCAACAGAGACTTCTTGGAA
GGAGTGTCTGGAGCAACATGGGTGGATTTGGTTCTCGAAGGCGACAGCTGCGTGACTATCATGTCTAAGG
ACAAGCCTACCATCGATGTGAAGATGATGAATATGGAGGCGGCCAACCTGGCAGAGGTCCGCAGTTATTG
CTATTTGGCTACCGTCAGCGATCTCTCCACCAAAGCTGCGTGCCCGACCATGGGAGAAGCTCACAATGAC
AAACGTGCTGACCCAGCTTTTGTGTGCAGACAAGGAGTGGTGGACAGGGGCTGGGGCAACGGCTGCGGAC
TATTTGGCAAAGGAAGCATTGACACATGCGCCAAATTTGCCTGCTCTACCAAGGCAATAGGAAGAACCAT
CTTGAAAGAGAATATCAAGTACGAAGTGGCCATTTTTGTCCATGGACCAACTACTGTGGAGTCGCACGGA
AACTACTCCACACAGGTTGGAGCCACTCAGGCAGGGAGACTCAGCATCACTCCTGCGGCGCCTTCATACA
CACTAAAGCTTGGAGAATATGGAGAGGTGACAGTGGACTGTGAACCACGGTCAGGGATTGACACCAATGC
ATACTACGTGATGACTGTTGGAACAAAGACGTTCTTGGTCCATCGTGAGTGGTTCATGGACCTCAACCTC
CCTTGGAGCAGTGCTGGAAGTACTGTGTGGAGGAACAGAGAGACGTTAATGGAGTTTGAGGAACCACACG
CCACGAAGCAGTCTGTGATAGCATTGGGCTCACAAGAGGGAGCTCTGCATCAAGCTTTGGCTGGAGCCAT
TCCTGTGGAATTTTCAAGCAACACTGTCAAGTTGACGTCGGGTCATTTGAAGTGTAGAGTGAAGATGGAA
AAATTGCAGTTGAAGGGAACAACCTATGGCGTCTGTTCAAAGGCTTTCAAGTTTCTTGGGACTCCCGCAG
ACACAGGTCACGGCACTGTGGTGTTGGAATTGCAGTACACTGGCACGGATGGACCTTGCAAAGTTCCTAT
CTCGTCAGTGGCTTCATTGAACGACCTAACGCCAGTGGGCAGATTGGTCACTGTCAACCCTTTTGTTTCA
GTGGCCACGGCCAACGCTAAGGTCCTGATTGAATTGGAACCACCCTTTGGAGACTCATACATAGTGGTGG
GCAGAGGAGAACAACAGATCAATCACCATTGGCACAAGTCTGGAAGCAGCATTGGCAAAGCCTTTACAAC
CACCCTCAAAGGAGCGCAGAGACTAGCCGCTCTAGGAGACACAGCTTGGGACTTTGGATCAGTTGGAGGG
GTGTTCACCTCAGTTGGGAAGGCTGTCCATCAAGTGTTCGGAGGAGCATTCCGCTCACTGTTCGGAGGCA
TGTCCTGGATAACGCAAGGATTGCTGGGGGCTCTCCTGTTGTGGATGGGCATCAATGCTCGTGATAGGTC
CATAGCTCTCACGTTTCTCGCAGTTGGAGGAGTTCTGCTCTTCCTCTCCGTGAACGTGCACGCTGACACT
GGGTGTGCCATAGACATCAGCCGGCAAGAGCTGAGATGTGGAAGTGGAGTGTTCATACACAATGATGTGG
AGGCTTGGATGGACCGGTACAAGTATTACCCTGAAACGCCACAAGGCCTAGCCAAGATCATTCAGAAAGC
TCATAAGGAAGGAGTGTGCGGTCTACGATCAGTTTCCAGACTGGAGCATCAAATGTGGGAAGCAGTGAAG
GACGAGCTGAACACTCTTTTGAAGGAGAATGGTGTGGACCTTAGTGTCGTGGTTGAGAAACAGGAGGGAA
TGTACAAGTCAGCACCTAAACGCCTCACCGCCACCACGGAAAAATTGGAAATTGGCTGGAAGGCCTGGGG
AAAGAGTATTTTATTTGCACCAGAACTCGCCAACAACACCTTTGTGGTTGATGGTCCGGAGACCAAGGAA
TGTCCGACTCAGAATCGCGCTTGGAATAGCTTAGAAGTGGAGGATTTTGGATTTGGTCTCACCAGCACTC
GGATGTTCCTGAAGGTCAGAGAGAGCAACACAACTGAATGTGACTCGAAGATCATTGGAACGGCTGTCAA
GAACAACTTGGCGATCCACAGTGACCTGTCCTATTGGATTGAAAGCAGGCTCAATGATACGTGGAAGCTT
GAAAGGGCAGTTCTGGGTGAAGTCAAATCATGTACGTGGCCTGAGACGCATACCTTGTGGGGCGATGGAA
TCCTTGAGAGTGACTTGATAATACCAGTCACACTGGCGGGACCACGAAGCAATCACAATCGGAGACCTGG
GTACAAGACACAAAACCAGGGCCCATGGGACGAAGGCCGGGTAGAGATTGACTTCGATTACTGCCCAGGA
ACTACGGTCACCCTGAGTGAGAGCTGCGGACACCGTGGACCTGCCACTCGCACCACCACAGAGAGCGGAA
AGTTGATAACAGATTGGTGCTGCAGGAGCTGCACCTTACCACCACTGCGCTACCAAACTGACAGCGGCTG
TTGGTATGGTATGGAGATCAGACCACAGAGACATGATGAAAAGACCCTCGTGCAGTCACAAGTGAATGCT
TATAATGCTGATATGATTGACCCTTTTCAGTTGGGCCTTCTGGTCGTGTTCTTGGCCACCCAGGAGGTCC
TTCGCAAGAGGTGGACAGCCAAGATCAGCATGCCAGCTATACTGATTGCTCTGCTAGTCCTGGTGTTTGG
GGGCATTACTTACACTGATGTGTTACGCTATGTCATCTTGGTGGGGGCAGCTTTCGCAGAATCTAATTCG
GGAGGAGACGTGGTACACTTGGCGCTCATGGCGACCTTCAAGATACAACCAGTGTTTATGGTGGCATCGT
TTCTCAAAGCGAGATGGACCAACCAGGAGAACATTTTGTTGATGTTGGCGGCTGTTTTCTTTCAAATGGC
TTATCACGATGCCCGCCAAATTCTGCTCTGGGAGATCCCTGATGTGTTGAATTCACTGGCGGTAGCTTGG
ATGATACTGAGAGCCATAACATTCACAACGACATCAAACGTGGTTGTTCCGCTGCTAGCCCTGCTAACAC
CCGGGCTGAGATGCTTGAATCTGGATGTGTACAGGATACTGCTGTTGATGGTCGGAATAGGCAGCTTGAT
CAGGGAGAAGAGGAGTGCAGCCGCAAAAAAGAAAGGAGCAAGTCTGCTATGCTTGGCTCTAGCCTCAACA
GGACTTTTCAACCCCATGATCCTTGCTGCTGGACTGATTGCATGTGATCCCAACCGTAAACGCGGATGGC
CCGCAACTGAAGTGATGACAGCTGTCGGCCTAATGTTTGCCATCGTCGGAGGGCTGGCAGAGCTTGACAT
TGACTCCATGGCCATTCCAATGACTATCGCGGGGCTCATGTTTGCTGCTTTCGTGATTTCTGGGAAATCA
ACAGATATGTGGATTGAGAGAACGGCGGACATTTCCTGGGAAAGTGATGCAGAAATTACAGGCTCGAGCG
AAAGAGTTGATGTGCGGCTTGATGATGATGGAAACTTCCAGCTCATGAATGATCCAGGAGCACCTTGGAA
GATATGGATGCTCAGAATGGTCTGTCTCGCGATTAGTGCGTACACCCCCTGGGCAATCTTGCCCTCAGTA
GTTGGATTTTGGATAACTCTCCAATACACAAAGAGAGGAGGCGTGTTGTGGGACACTCCCTCACCAAAGG
AGTACAAAAAGGGGGACACGACCACCGGCGTCTACAGGATCATGACTCGTGGGCTGCTCGGCAGTTATCA
AGCAGGAGCGGGCGTGATGGTTGAAGGTGTTTTCCACACCCTTTGGCATACAACAAAAGGAGCCGCTTTG
ATGAGCGGAGAGGGCCGCCTGGACCCATACTGGGGCAGTGTCAAGGAGGATCGACTTTGTTACGGAGGAC
CCTGGAAATTGCAGCACAAGTGGAACGGGCAGGATGAGGTGCAGATGATTGTGGTGGAACCTGGCAAGAA
CGTTAAGAACGTCCAGACGAAACCAGGGGTGTTCAAAACACCTGAAGGAGAAATCGGGGCCGTGACTTTG
GACTTCCCCACTGGAACATCAGGCTCACCAATAGTGGACAAAAACGGTGATGTGATTGGGCTTTATGGCA
ATGGAGTCATAATGCCCAACGGCTCATACATAAGCGCGATAGTGCAGGGTGAAAGGATGGATGAGCCAAT
CCCAGCCGGATTCGAACCTGAGATGCTGAGGAAAAAACAGATCACTGTACTGGATCTCCATCCCGGCGCC
GGTAAAACAAGGAGGATTCTGCCACAGATCATCAAAGAGGCCATAAACAGAAGACTGAGAACAGCCGTGC
TAGCGCCAACCAGGGTTGTGGCTGCTGAGATGGCTGAAGCACTGAGAGGACTGCCCATCCGGTACCAGAC
ATCCGCAGTGCCCAGAGAACATAATGGAAATGAGATTGTTGATGTCATGTGTCATGCTACCCTCACCCAC
AGGCTGATGTCTCCTCACAGGGTGCCGAACTACAACCTGTTCGTGATGGATGAGGCTCATTTCACCGACC
CAGCTAGCATTGCAGCAAGAGGTTACATTTCCACAAAGGTCGAGCTAGGGGAGGCGGCGGCAATATTCAT
GACAGCCACCCCACCAGGCACTTCAGATCCATTCCCAGAGTCCAATTCACCAATTTCCGACTTACAGACT
GAGATCCCGGATCGAGCTTGGAACTCTGGATACGAATGGATCACAGAATACACCGGGAAGACGGTTTGGT
TTGTGCCTAGTGTCAAGATGGGGAATGAGATTGCCCTTTGCCTACAACGTGCTGGAAAGAAAGTAGTCCA
ATTGAACAGAAAGTCGTACGAGACGGAGTACCCAAAATGTAAGAACGATGATTGGGACTTTGTTATCACA
ACAGACATATCTGAAATGGGGGCTAACTTCAAGGCGAGCAGGGTGATTGACAGCCGGAAGAGTGTGAAAC
CAACCATCATAACAGAAGGAGAAGGGAGAGTGATCCTGGGAGAACCATCTGCAGTGACAGCAGCTAGTGC
CGCCCAGAGACGTGGACGTATCGGTAGAAATCCGTCGCAAGTTGGTGATGAGTACTGTTATGGGGGGCAC
ACGAATGAAGACGACTCGAACTTCGCCCATTGGACTGAGGCACGAATCATGCTGGACAACATCAACATGC
CAAACGGACTGATCGCTCAATTCTACCAACCAGAGCGTGAGAAGGTATATACCATGGATGGGGAATACCG
GCTCAGAGGAGAAGAGAGAAAAAACTTTCTGGAACTGTTGAGGACTGCAGATCTGCCAGTTTGGCTGGCT
TACAAGGTTGCAGCGGCTGGAGTGTCATACCACGACCGGAGGTGGTGCTTTGATGGTCCTAGGACAAACA
CAATTTTAGAAGACAACAACGAAGTGGAAGTCATCACGAAGCTTGGTGAAAGGAAGATTCTGAGGCCGCG
CTGGATTGATGCCAGGGTGTACTCGGATCACCAGGCACTAAAGGCGTTCAAGGACTTCGCCTCGGGAAAA
CGTTCTCAGATAGGGCTCATTGAGGTTCTGGGAAAGATGCCTGAGCACTTCATGGGGAAGACATGGGAAG
CACTTGACACCATGTACGTTGTGGCCACTGCAGAGAAAGGAGGAAGAGCTCACAGAATGGCCCTGGAGGA
ACTGCCAGATGCTCTTCAGACAATTGCCTTGATTGCCTTATTGAGTGTGATGACCATGGGAGTATTCTTC
CTCCTCATGCAGCGGAAGGGCATTGGAAAGATAGGTTTGGGAGGCGCTGTCTTGGGAGTCGCGACCTTTT
TCTGTTGGATGGCTGAAGTTCCAGGAACGAAGATCGCCGGAATGTTGCTGCTCTCCCTTCTCTTGATGAT
TGTGCTAATTCCTGAGCCAGAGAAGCAACGTTCGCAGACAGACAACCAGCTAGCCGTGTTCCTGATTTGT
GTCATGACCCTTGTGAGCGCAGTGGCAGCCAACGAGATGGGTTGGCTAGATAAGACCAAGAGTGACATAA
GCAGTTTGTTTGGGCAAAGAATTGAGGTCAAGGAGAATTTCAGCATGGGAGAGTTTCTTCTGGACTTGAG
GCCGGCAACAGCCTGGTCACTGTACGCTGTGACAACAGCGGTCCTCACTCCACTGCTAAAGCATTTGATC
ACGTCAGATTACATCAACACCTCATTGACCTCAATAAACGTTCAGGCAAGTGCACTATTCACACTCGCGC
GAGGCTTCCCCTTCGTCGATGTTGGAGTGTCGGCTCTCCTGCTAGCAGCCGGATGCTGGGGACAAGTCAC
CCTCACCGTTACGGTAACAGCGGCAACACTCCTTTTTTGCCACTATGCCTACATGGTTCCCGGTTGGCAA
GCTGAGGCAATGCGCTCAGCCCAGCGGCGGACAGCGGCCGGAATCATGAAGAACGCTGTAGTGGATGGCA
TCGTGGCCACGGACGTCCCAGAATTAGAGCGCACCACACCCATCATGCAGAAGAAAGTTGGACAGATCAT
GCTGATCTTGGTGTCTCTAGCTGCAGTAGTAGTGAACCCGTCTGTGAAGACAGTACGAGAAGCCGGAATT
TTGATCACGGCCGCAGCGGTGACGCTTTGGGAGAATGGAGCAAGCTCTGTTTGGAACGCAACAACTGCCA
TCGGACTCTGCCACATCATGCGTGGGGGTTGGTTGTCATGTCTATCCATAACATGGACACTCATAAAGAA
CATGGAAAAACCAGGACTAAAAAGAGGTGGGGCAAAAGGACGCACCTTGGGAGAGGTTTGGAAAGAAAGA
CTCAACCAGATGACAAAAGAAGAGTTCACTAGGTACCGCAAAGAGGCCATCATCGAAGTCGATCGCTCAG
CGGCAAAACACGCCAGGAAAGAAGGCAATGTCACTGGAGGGCATCCAGTCTCTAGGGGCACAGCAAAACT
GAGATGGCTGGTCGAACGGAGGTTTCTCGAACCGGTCGGAAAAGTGATTGACCTTGGATGTGGAAGAGGC
GGTTGGTGTTACTATATGGCAACCCAAAAAAGAGTCCAAGAAGTCAGAGGGTACACAAAGGGCGGTCCCG
GACATGAAGAGCCCCAACTAGTGCAAAGTTATGGATGGAACATTGTCACCATGAAGAGTGGAGTGGATGT
GTTCTACAGACCTTCTGAGTGTTGTGACACCCTCCTTTGTGACATCGGAGAGTCCTCGTCAAGTGCTGAG
GTTGAAGAGCATAGGACGATTCGGGTCCTTGAAATGGTTGAGGACTGGCTGCACCGAGGGCCAAGGGAAT
TTTGCGTGAAGGTGCTCTGTCCCTACATGCCGAAAGTCATAGAGAAGATGGAGCTGCTCCAACGCCGGTA
TGGGGGGGGACTGGTCAGAAACCCACTCTCACGGAATTCCACGCACGAGATGTATTGGGTGAGTCGAGCT
TCAGGCAATGTGGTACATTCAGTGAATATGACCAGCCAGGTGCTCCTAGGAAGAATGGAAAAAAGGACCT
GGAAGGGACCCCAATACGAGGAAGATGTAAACTTGGGAAGTGGAACCAGGGCGGTGGGAAAACCCCTGCT
CAACTCAGACACCAGTAAAATCAAGAACAGGATTGAACGACTCAGGCGTGAGTACAGTTCGACGTGGCAC
CACGATGAGAACCACCCATATAGAACCTGGAACTATCACGGCAGTTATGATGTGAAGCCCACAGGCTCCG
CCAGTTCGCTGGTCAATGGAGTGGTCAGGCTCCTCTCAAAACCATGGGACACCATCACGAATGTTACCAC
CATGGCCATGACTGACACTACTCCCTTCGGGCAGCAGCGAGTGTTCAAAGAGAAGGTGGACACGAAAGCT
CCTGAACCGCCAGAAGGAGTGAAGTACGTGCTCAACGAGACCACCAACTGGTTGTGGGCGTTTTTGGCCA
GAGAAAAACGTCCCAGAATGTGCTCTCGAGAGGAATTCATAAGAAAGGTCAACAGCAATGCAGCTTTGGG
TGCCATGTTTGAAGAGCAGAATCAATGGAGGAGCGCCAGAGAAGCAGTTGAAGATCCAAAATTTTGGGAG
ATGGTGGATGAGGAGCGCGAGGCACATCTGCGGGGGGAATGTCACACTTGCATTTACAACATGATGGGAA
AGAGAGAGAAAAAACCCGGAGAGTTCGGAAAGGCCAAGGGAAGCAGAGCCATTTGGTTCATGTGGCTCGG
AGCTCGCTTTCTGGAGTTCGAGGCTCTGGGTTTTCTCAATGAAGACCACTGGCTTGGAAGAAAGAACTCA
GGAGGAGGTGTCGAGGGCTTGGGCCTCCAAAAACTGGGTTACATCCTGCGTGAAGTTGGCACCCGGCCTG
GGGGCAAGATCTATGCTGATGACACAGCTGGCTGGGACACCCGCATCACGAGAGCTGACTTGGAAAATGA
AGCTAAGGTGCTTGAGCTGCTTGATGGGGAACATCGGCGTCTTGCCAGGGCCATCATTGAGCTCACCTAT
CGTCACAAAGTTGTGAAAGTGATGCGCCCGGCTGCTGATGGAAGAACCGTCATGGATGTTATCTCCAGAG
AAGATCAGAGGGGGAGTGGACAAGTTGTCACCTACGCCCTAAACACTTTCACCAACCTGGCCGTCCAGCT
GGTGAGGATGATGGAAGGGGAAGGAGTGATTGGCCCAGATGATGTGGAGAAACTCACAAAAGGGAAAGGA
CCCAAAGTCAGGACCTGGCTGTTTGAGAATGGGGAAGAAAGACTCAGCCGCATGGCTGTCAGTGGAGATG
ACTGTGTGGTAAAGCCCCTGGACGATCGCTTTGCCACCTCGCTCCACTTCCTCAATGCTATGTCAAAGGT
TCGCAAAGACATCCAAGAGTGGAAACCGTCAACTGGATGGTATGATTGGCAGCAGGTTCCATTTTGCTCA
AACCATTTCACTGAATTGATCATGAAAGATGGAAGAACACTGGTGGTTCCATGCCGAGGACAGGATGAAT
TGGTAGGCAGAGCTCGCATATCTCCAGGGGCCGGATGGAACGTCCGCGACACTGCTTGTCTGGCTAAGTC
TTATGCCCAGATGTGGCTGCTTCTGTACTTCCACAGAAGAGACCTGCGGCTCATGGCCAACGCCATTTGC
TCCGCTGTCCCTGTGAATTGGGTCCCTACCGGAAGAACCACGTGGTCCATCCATGCAGGAGGAGAGTGGA
TGACAACAGAGGACATGTTGGAGGTCTGGAACCGTGTTTGGATAGAGGAGAATGAATGGATGGAAGACAA
AACCCCAGTGGAGAAATGGAGTGACGTCCCATATTCAGGAAAACGAGAGGACATCTGGTGTGGCAGCCTG
ATTGGCACAAGAGCCCGAGCCACGTGGGCAGAAAACATCCAGGTGGCTATCAACCAAGTCAGAGCAATCA
TCGGAGATGAGAAGTATGTGGACTACATGAGTTCACTAAAGAGATATGAAGACACAACTTTGGTTGAGGA
CACAGTACTGTA

Protein Sequence : Show Sequence

>gi|158516888|ref|YP_001527877.1| polyprotein [West Nile virus]
MSKKPGGPGKSRAVNMLKRGMPRVLSLIGLKRAMLSLIDGKGPIRFVLALLAFFRFTAIAPTRAVLDRWR
GVNKQTAMKHLLSFKKELGTLTSAINRRSSKQKKRGGKTGIAVMIGLIASVGAVTLSNFQGKVMMTVNAT
DVTDVITIPTAAGKNLCIVRAMDVGYMCDDTITYECPVLSAGNDPEDIDCWCTKSAVYVRYGRCTKTRHS
RRSRRSLTVQTHGESTLANKKGAWMDSTKATRYLVKTESWILRNPGYALVAAVIGWMLGSNTMQRVVFVV
LLLLVAPAYSFNCLGMSNRDFLEGVSGATWVDLVLEGDSCVTIMSKDKPTIDVKMMNMEAANLAEVRSYC
YLATVSDLSTKAACPTMGEAHNDKRADPAFVCRQGVVDRGWGNGCGLFGKGSIDTCAKFACSTKAIGRTI
LKENIKYEVAIFVHGPTTVESHGNYSTQVGATQAGRLSITPAAPSYTLKLGEYGEVTVDCEPRSGIDTNA
YYVMTVGTKTFLVHREWFMDLNLPWSSAGSTVWRNRETLMEFEEPHATKQSVIALGSQEGALHQALAGAI
PVEFSSNTVKLTSGHLKCRVKMEKLQLKGTTYGVCSKAFKFLGTPADTGHGTVVLELQYTGTDGPCKVPI
SSVASLNDLTPVGRLVTVNPFVSVATANAKVLIELEPPFGDSYIVVGRGEQQINHHWHKSGSSIGKAFTT
TLKGAQRLAALGDTAWDFGSVGGVFTSVGKAVHQVFGGAFRSLFGGMSWITQGLLGALLLWMGINARDRS
IALTFLAVGGVLLFLSVNVHADTGCAIDISRQELRCGSGVFIHNDVEAWMDRYKYYPETPQGLAKIIQKA
HKEGVCGLRSVSRLEHQMWEAVKDELNTLLKENGVDLSVVVEKQEGMYKSAPKRLTATTEKLEIGWKAWG
KSILFAPELANNTFVVDGPETKECPTQNRAWNSLEVEDFGFGLTSTRMFLKVRESNTTECDSKIIGTAVK
NNLAIHSDLSYWIESRLNDTWKLERAVLGEVKSCTWPETHTLWGDGILESDLIIPVTLAGPRSNHNRRPG
YKTQNQGPWDEGRVEIDFDYCPGTTVTLSESCGHRGPATRTTTESGKLITDWCCRSCTLPPLRYQTDSGC
WYGMEIRPQRHDEKTLVQSQVNAYNADMIDPFQLGLLVVFLATQEVLRKRWTAKISMPAILIALLVLVFG
GITYTDVLRYVILVGAAFAESNSGGDVVHLALMATFKIQPVFMVASFLKARWTNQENILLMLAAVFFQMA
YHDARQILLWEIPDVLNSLAVAWMILRAITFTTTSNVVVPLLALLTPGLRCLNLDVYRILLLMVGIGSLI
REKRSAAAKKKGASLLCLALASTGLFNPMILAAGLIACDPNRKRGWPATEVMTAVGLMFAIVGGLAELDI
DSMAIPMTIAGLMFAAFVISGKSTDMWIERTADISWESDAEITGSSERVDVRLDDDGNFQLMNDPGAPWK
IWMLRMVCLAISAYTPWAILPSVVGFWITLQYTKRGGVLWDTPSPKEYKKGDTTTGVYRIMTRGLLGSYQ
AGAGVMVEGVFHTLWHTTKGAALMSGEGRLDPYWGSVKEDRLCYGGPWKLQHKWNGQDEVQMIVVEPGKN
VKNVQTKPGVFKTPEGEIGAVTLDFPTGTSGSPIVDKNGDVIGLYGNGVIMPNGSYISAIVQGERMDEPI
PAGFEPEMLRKKQITVLDLHPGAGKTRRILPQIIKEAINRRLRTAVLAPTRVVAAEMAEALRGLPIRYQT
SAVPREHNGNEIVDVMCHATLTHRLMSPHRVPNYNLFVMDEAHFTDPASIAARGYISTKVELGEAAAIFM
TATPPGTSDPFPESNSPISDLQTEIPDRAWNSGYEWITEYTGKTVWFVPSVKMGNEIALCLQRAGKKVVQ
LNRKSYETEYPKCKNDDWDFVITTDISEMGANFKASRVIDSRKSVKPTIITEGEGRVILGEPSAVTAASA
AQRRGRIGRNPSQVGDEYCYGGHTNEDDSNFAHWTEARIMLDNINMPNGLIAQFYQPEREKVYTMDGEYR
LRGEERKNFLELLRTADLPVWLAYKVAAAGVSYHDRRWCFDGPRTNTILEDNNEVEVITKLGERKILRPR
WIDARVYSDHQALKAFKDFASGKRSQIGLIEVLGKMPEHFMGKTWEALDTMYVVATAEKGGRAHRMALEE
LPDALQTIALIALLSVMTMGVFFLLMQRKGIGKIGLGGAVLGVATFFCWMAEVPGTKIAGMLLLSLLLMI
VLIPEPEKQRSQTDNQLAVFLICVMTLVSAVAANEMGWLDKTKSDISSLFGQRIEVKENFSMGEFLLDLR
PATAWSLYAVTTAVLTPLLKHLITSDYINTSLTSINVQASALFTLARGFPFVDVGVSALLLAAGCWGQVT
LTVTVTAATLLFCHYAYMVPGWQAEAMRSAQRRTAAGIMKNAVVDGIVATDVPELERTTPIMQKKVGQIM
LILVSLAAVVVNPSVKTVREAGILITAAAVTLWENGASSVWNATTAIGLCHIMRGGWLSCLSITWTLIKN
MEKPGLKRGGAKGRTLGEVWKERLNQMTKEEFTRYRKEAIIEVDRSAAKHARKEGNVTGGHPVSRGTAKL
RWLVERRFLEPVGKVIDLGCGRGGWCYYMATQKRVQEVRGYTKGGPGHEEPQLVQSYGWNIVTMKSGVDV
FYRPSECCDTLLCDIGESSSSAEVEEHRTIRVLEMVEDWLHRGPREFCVKVLCPYMPKVIEKMELLQRRY
GGGLVRNPLSRNSTHEMYWVSRASGNVVHSVNMTSQVLLGRMEKRTWKGPQYEEDVNLGSGTRAVGKPLL
NSDTSKIKNRIERLRREYSSTWHHDENHPYRTWNYHGSYDVKPTGSASSLVNGVVRLLSKPWDTITNVTT
MAMTDTTPFGQQRVFKEKVDTKAPEPPEGVKYVLNETTNWLWAFLAREKRPRMCSREEFIRKVNSNAALG
AMFEEQNQWRSAREAVEDPKFWEMVDEEREAHLRGECHTCIYNMMGKREKKPGEFGKAKGSRAIWFMWLG
ARFLEFEALGFLNEDHWLGRKNSGGGVEGLGLQKLGYILREVGTRPGGKIYADDTAGWDTRITRADLENE
AKVLELLDGEHRRLARAIIELTYRHKVVKVMRPAADGRTVMDVISREDQRGSGQVVTYALNTFTNLAVQL
VRMMEGEGVIGPDDVEKLTKGKGPKVRTWLFENGEERLSRMAVSGDDCVVKPLDDRFATSLHFLNAMSKV
RKDIQEWKPSTGWYDWQQVPFCSNHFTELIMKDGRTLVVPCRGQDELVGRARISPGAGWNVRDTACLAKS
YAQMWLLLYFHRRDLRLMANAICSAVPVNWVPTGRTTWSIHAGGEWMTTEDMLEVWNRVWIEENEWMEDK
TPVEKWSDVPYSGKREDIWCGSLIGTRARATWAENIQVAINQVRAIIGDEKYVDYMSSLKRYEDTTLVED
TVL

Molecule Role : Other

3. envelope (E) proteins

Gene Name : envelope (E) proteins
Sequence Strain (Species/Organism) : Japanese encephalitis virus
NCBI Protein GI : P27395
Other Database IDs : CDD:250285
CDD:279856
CDD:279358
CDD:279241
CDD:213392
CDD:213897
CDD:279316
CDD:279359
CDD:279357
CDD:279317
CDD:214692
CDD:284962
CDD:238005
CDD:304359
CDD:238034
CDD:279666
CDD:279665
CDD:279986
CDD:279336
Taxonomy ID : 11073
Protein Name : Genome polyprotein
Protein pI : 8.58
Protein Weight : 367996.94
Protein Length : 4486
Protein Note : Genome polyprotein. /FTId=PRO_0000405188.

Protein Sequence : Show Sequence

>sp|P27395.1|POLG_JAEV1 RecName: Full=Genome polyprotein; Contains: RecName: Full=Capsid protein C; AltName: Full=Core protein; Contains: RecName: Full=Protein prM; Contains: RecName: Full=Peptide pr; Contains: RecName: Full=Small envelope protein M; AltName: Full=Matrix protein; Contains: RecName: Full=Envelope protein E; Contains: RecName: Full=Non-structural protein 1; Short=NS1; Contains: RecName: Full=Non-structural protein 2A; Short=NS2A; Contains: RecName: Full=Serine protease subunit NS2B; AltName: Full=Flavivirin protease NS2B regulatory subunit; AltName: Full=Non-structural protein 2B; Contains: RecName: Full=Serine protease NS3; AltName: Full=Flavivirin protease NS3 catalytic subunit; AltName: Full=Non-structural protein 3; Contains: RecName: Full=Non-structural protein 4A; Short=NS4A; Contains: RecName: Full=Peptide 2k; Contains: RecName: Full=Non-structural protein 4B; Short=NS4B; Contains: RecName: Full=RNA-directed RNA polymerase NS5; AltName: Full=Non-structural protein 5
MTKKPGGPGKNRAINMLKRGLPRVFPLVGVKRVVMSLLDGRGPVRFVLALITFFKFTALAPTKALLGRWK
AVEKSVAMKHLTSFKRELGTLIDAVNKRGRKQNKRGGNEGSIMWLASLAVVIACAGAMKLSNFQGKLLMT
INNTDIADVIVIPTSKGENRCWVRAIDVGYMCEDTITYECPKLTMGNDPEDVDCWCDNQEVYVQYGRCTR
TRHSKRSRRSVSVQTHGESSLVNKKEAWLDSTKATRYLMKTENWIIRNPGYAFLAAVLGWMLGSNNGQRV
VFTILLLLVAPAYSFNCLGMGNRDFIEGASGATWVDLVLEGDSCLTIMANDKPTLDVRMINIEASQLAEV
RSYCYHASVTDISTVARCPTTGEAHNEKRADSSYVCKQGFTDRGWGNGCGLFGKGSIDTCAKFSCTSKAI
GRTIQPENIKYEVGIFVHGTTTSENHGNYSAQVGASQAAKFTVTPNAPSITLKLGDYGEVTLDCEPRSGL
NTEAFYVMTVGSKSFLVHREWFHDLALPWTSPSSTAWRNRELLMEFEGAHATKQSVVALGSQEGGLHQAL
AGAIVVEYSSSVKLTSGHLKCRLKMDKLALKGTTYGMCTEKFSFAKNPVDTGHGTVVIELSYSGSDGPCK
IPIVSVASLNDMTPVGRLVTVNPFVATSSANSKVLVEMEPPFGDSYIVVGRGDKQINHHWHKAGSTLGKA
FSTTLKGAQRLAALGDTAWDFGSIGGVFNSIGRAVHQVFGGAFRTLFGGMSWITQGLMGALLLWMGVNAR
DRSIALAFLATGGVLVFLATNVHADTGCAIDITRKEMRCGSGIFVHNDVEAWVDRYKYLPETPRSLAKIV
HKAHKEGVCGVRSVTRLEHQMWEAVRDELNVLLKENAVDLSVVVNKPVGRYRSAPKRLSMTQEKFEMGWK
AWGKSILFAPELANSTFVVDGPETKECPDEHRAWNSMQIEDFGFGITSTRVWLKIREESTDECDGAIIGT
AVKGHVAVHSDLSYWIESRYNDTWKLERAVFGEVKSCTWPETHTLWGDDVEESELIIPHTIAGPKSKHNR
REGYKTQNQGPWDENGIVLDFDYCPGTKVTITEDCSKRGPSVRTTTDSGKLITDWCCRSCSLPPLRFRTE
NGCWYGMEIRPVMHDETTLVRSQVDAFKGEMVDPFQLGLLVMFLATQEVLRKRWTARLTIPAVLGVLLVL
MLGGITYTDLARYVVLVAAAFAEANSGGDVLHLALIAVFKIQPAFLVMNMLSTRWTNQENVILVLGAAFF
QLASVDLQIGVHGILNAAAIAWMIVRAITFPTTSSVTMPVLALLTPGMRALYLDTYRIILLVIGICSLLH
ERKKTMAKKKGAVLLGLALTSTGWFSPTTIAAGLMVCNPNKKRGWPATEFLSAVGLMFAIVGGLAELDIE
SMSIPFMLAGLMAVSYVVSGKATDMWLERAADISWEMDAAITGSSRRLDVKLDDDGDFHLIDDPGVPWKV
WVLRMSCIGLAALTPWAIVPAAFGYWLTLKTTKRGGVFWDTPSPKPCSKGDTTTGVYRIMARGILGTYQA
GVGVMYENVFHTLWHTTRGAAIMSGEGKLTPYWGSVREDRIAYGGPWRFDRKWNGTDDVQVIVVEPGKAA
VNIQTKPGVFRTPFGEVGAVSLDYPRGTSGSPILDSNGDIIGLYGNGVELGDGSYVSAIVQGDRQEEPVP
EAYTPNMLRKRQMTVLDLHPGSGKTRKILPQIIKDAIQQRLRTAVLAPTRVVAAEMAEALRGLPVRYQTS
AVQREHQGNEIVDVMCHATLTHRLMSPNRVPNYNLFVMDEAHFTDPASIAARGYIATKVELGEAAAIFMT
ATPPGTTDPFPDSNAPIHDLQDEIPDRAWSSGYEWITEYAGKTVWFVASVKMGNEIAMCLQRAGKKVIQL
NRKSYDTEYPKCKNGDWDFVITTDISEMGANFGASRVIDCRKSVKPTILEEGEGRVILGNPSPITSASAA
QRRGRVGRNPNQVGDEYHYGGATSEDDSNLAHWTEAKIMLDNIHMPNGLVAQLYGPEREKAFTMDGEYRL
RGEEKKNFLELLRTADLPVWLAYKVASNGIQYTDRKWCFDGPRTNAILEDNTEVEIVTRMGERKILKPRW
LDARVYADHQALKWFKDFAAGKRSAVSFIEVLGRMPEHFMGKTREALDTMYLVATAEKGGKAHRMALEEL
PDALETITLIVAITVMTGGFFLLMMQRKGIGKMGLGALVLTLATFFLWAAEVPGTKIAGTLLIALLLMVV
LIPEPEKQRSQTDNQLAVFLICVLTVVGVVAANEYGMLEKTKADLKSMFGGKTQASGLTGLPSMALDLRP
ATAWALYGGSTVVLTPLLKHLITSEYVTTSLASINSQAGSLFVLPRGVPFTDLDLTVGLVFLGCWGQITL
TTFLTAMVLATLHYGYMLPGWQAEALRAAQRRTAAGIMKNAVVDGMVATDVPELERTTPLMQKKVGQVLL
IGVSVAAFLVNPNVTTVREAGVLVTAATLTLWDNGASAVWNSTTATGLCHVMRGSYLAGGSIAWTLIKNA
DKPSLKRGRPGGRTLGEQWKEKLNAMSREEFFKYRREAIIEVDRTEARRARRENNIVGGHPVSRGSAKLR
WLVEKGFVSPIGKVIDLGCGRGGWSYYAATLKKVQEVRGYTKGGAGHEEPMLMQSYGWNLVSLKSGVDVF
YKPSEPSDTLFCDIGESSPSPEVEEQRTLRVLEMTSDWLHRGPREFCIKVLCPYMPKVIEKMEVLQRRFG
GGLVRLPLSRNSNHEMYWVSGAAGNVVHAVNMTSQVLLGRMDRTVWRGPKYEEDVNLGSGTRAVGKGEVH
SNQEKIKKRIQKLKEEFATTWHKDPEHPYRTWTYHGSYEVKATGSASSLVNGVVELMSKPWDAIANVTTM
AMTDTTPFGQQRVFKEKVDTKAPEPPAGAKEVLNETTNWLWAHLSREKRPRLCTKEEFIKKVNSNAALGA
VFAEQNQWSTAREAVDDPRFWEMVDEERENHLRGECHTCIYNMMGKREKKPGEFGKAKGSRAIWFMWLGA
RYLEFEALGFLNEDHWLSRENSGGGVEGSGVQKLGYILRDIAGKQGGKMYADDTAGWDTRITRTDLENEA
KVLELLDGEHRMLARAIIELTYRHKVVKVMRPAAEGKTVMDVISREDQRGSGQVVTYALNTFTNIAVQLV
RLMEAEGVIGPQHLEQLPRKTKIAVRTWLFENGEERVTRMAISGDDCVVKPLDDRFATALHFLNAMSKVR
KDIQEWKPSHGWHDWQQVPFCSNHFQEIVMKDGRSIVVPCRGQDELIGRARISPGAGWNVKDTACLAKAY
AQMWLLLYFHRRDLRLMANAICSAVPVDWVPTGRTSWSIHSKGEWMTTEDMLQVWNRVWIEENEWMMDKT
PITSWTDVPYVGKREDIWCGSLIGTRSRATWAENIYAAINQVRAVIGKENYVDYMTSLRRYEDVLIQEDR
VI

Molecule Role : Protective antigen
Molecule Role Annotation : (Qian et al., 2015)

4. M protein

Gene Name : M protein
Sequence Strain (Species/Organism) : Japanese encephalitis virus strain TS3306
NCBI Protein GI : 4572323
Other Database IDs : CDD:279856
Taxonomy ID : 11072
Gene Strand (Orientation) : ?
Protein Name : M protein
Protein pI : 5.84
Protein Weight : 10361.74
Protein Length : 156
Protein Note : isolated from the Torres Strait

Protein Sequence : Show Sequence

>AAD23744.1 M protein, partial [Japanese encephalitis virus]
MKLSNFQGKLLMTVNNTDIADVIVIPTSKGENRCWVRAIDVGYMCEDTITYECPKLTTGNDPEDVDCWCD
NQEVYIQYGRCTRTRHSKRSRR

Molecule Role : Protective antigen
Related Vaccine(s): Japanese encephalitis virus DNA Vaccine P-JEV

5. NS1

Gene Name : NS1
Sequence Strain (Species/Organism) : Japanese encephalitis virus
VO ID : VO_0011147
NCBI Protein GI : 18418672
Other Database IDs : CDD:279316
Taxonomy ID : 11072
Gene Strand (Orientation) : ?
Protein Name : NS1 protein
Protein pI : 8.12
Protein Weight : 16884.93
Protein Length : 218
Protein Note : isolated from porcine sera

Protein Sequence : Show Sequence

>AAL68990.1 NS1 protein, partial [Japanese encephalitis virus]
ELIIPHTIAGPRSKHNRREGYKTQNQGPWDENGIVLDFDYCPGTKVTITEDCGKRGPSIRTTTDSGKLIT
DWCCRSCSLPPLRFRTENGCWYGMEIRPVRHDETTLVRSQVDAFNGEMIDPFQLGLLVMFLATQEVLRKR
WTARLTIPAVL

Molecule Role : Protective antigen
Molecule Role Annotation : Balb/c mice and swine vaccinated with TK(-)/gG(-)/NS1(+) expressing NS1 protein of JEV could confer protective immunity against lethal challenge of the virulent PRV Ea strain and develop a good humoral and cellular immune response against JEV (Xu et al., 2004).
Related Vaccine(s): Japanese encephalitis virus DNA vaccine encoding NS1 (pUSK-NS1) , Japanese encephalitis virus DNA Vaccine P-JEV , NYVAC-JEV- prM/E/ NS1

6. NS1

Gene Name : NS1
Sequence Strain (Species/Organism) : Japanese encephalitis virus
NCBI Protein GI : AOG16026
Taxonomy ID : 11072
Protein Name : NS1
Protein pI : 6.75
Protein Weight : 17675.73
Protein Length : 223

Protein Sequence : Show Sequence

>AOG16026.1 NS1, partial [Japanese encephalitis virus]
DVEESELIIPHTIAGPKSKHNRREGYKTQNQGPWDENGIVLDFDYCPGTKVTITEDCGKRGPSVRTTTDS
GKLITDWCCRSCSLPPLRFRTENGCWYGMEIRPVRHDETTLVRSQVDAFNGEMVDPFQLGLLVMFLATQE
VLRKRWTARLTIPAVLGALLVLML

Molecule Role : Protective antigen
Molecule Role Annotation : (Hua et al., 2014)

7. NS3

Gene Name : NS3
Sequence Strain (Species/Organism) : Japanese encephalitis virus
VO ID : VO_0011148
NCBI Protein GI : 27696332
Other Database IDs : CDD:279317
CDD:214692
CDD:284962
CDD:238005
CDD:304359
CDD:238034
Taxonomy ID : 11072
Gene Strand (Orientation) : ?
Protein Name : non-structural protein NS3
Protein pI : 7.14
Protein Weight : 64684.98
Protein Length : 699
Protein Note : proteinase and putative helicase

Protein Sequence : Show Sequence

>NP_775670.1 non-structural protein NS3 [Japanese encephalitis virus]
GGVFWDTPSPKPCSKGDTTTGVYRIMARGILGTYQAGVGVMYENVFHTLWHTTRGAAIMSGEGKLTPYWG
SVKEDRIAYGGPWRFDRKWNGTDDVQVIVVEPGKAAVNIQTKPGVFRTPFGEVGAVSLDYPRGTSGSPIL
DSNGDIIGLYGNGVELGDGSYVSAIVQGDRQEEPVPEAYTPNMLRKRQMTVLDLHPGSGKTRKILPQIIK
DAIQQRLRTAVLAPTRVVAAEMAEALRGLPVRYQTSAVQREHQGNEIVDVMCHATLTHRLMSPNRVPNYN
LFVMDEAHFTDPASIAARGYIATKVELGEAAAIFMTATPPGTTDPFPDSNAPIHDLQDEIPDRAWSSGYE
WITEYAGKTVWFVASVKMGNEIAMCLQRAGKKVIQLNRKSYDTEYPKCKNGDWDFVITTDISEMGANFGA
SRVIDCRKSVKPTILEEGEGRVILGNPSPITSASAAQRRGRVGRNPNQVGDEYHYGGATSEDDSNLAHWT
EAKIMLDNIHMPNGLVAQLYGPEREKAFTMDGEYRLRGEEKKNFLELLRTADLPVWLAYKVASNGIQYTD
RRWCFDGPRTNAILEDNTEVEIVTRMGERKILKPRWLDARVYADHQALKWFKDFAAGKR

Molecule Role : Protective antigen
Molecule Role Annotation : Researchers constructed plasmid DNAs encoding JE virus proteins. Cytotoxic T lymphocytes (CTLs) were induced by NS3 in a mouse model. Three immunizations with pUJENS3 provided a 50% partial protection from a lethal dose of JE virus (Konishi et al., 2003).
Related Vaccine(s): Japanese encephalitis virus DNA vaccine pUJENS3

8. NS5

Gene Name : NS5
Sequence Strain (Species/Organism) : Japanese encephalitis virus
VO ID : VO_0011149
NCBI Protein GI : 158702649
Other Database IDs : CDD:279336
Taxonomy ID : 11072
Gene Strand (Orientation) : ?
Protein Name : NS5
Protein pI : 9.89
Protein Weight : 8854.45
Protein Length : 135
Protein Note : Flavivirus RNA-directed RNA polymerase; pfam00972

Protein Sequence : Show Sequence

>ABW77689.1 NS5, partial [Japanese encephalitis virus]
KREKKPGEFGKAKGSRAIWFMWLGARYLEFEALGFLNEDHWLSRENSGGGVEGSGVQKLGYILRDIAGKQ
GGKMYAD

Molecule Role : Protective antigen
Molecule Role Annotation : Researchers constructed plasmid DNAs encoding JE virus proteins. Cytotoxic T lymphocytes (CTLs) were induced by NS5 in a mouse model. Three immunizations with pUJENS5 provided a 57% partial protection from a lethal dose of JE virus (Konishi et al., 2003).
Related Vaccine(s): Japanese encephalitis virus DNA vaccine pUJENS5

9. PreM

Gene Name : PreM
Sequence Strain (Species/Organism) : Japanese encephalitis virus
VO ID : VO_0011150
NCBI Protein GI : 14600066
Other Database IDs : CDD:279856
CDD:279358
Taxonomy ID : 11072
Gene Strand (Orientation) : ?
Protein Name : preM protein
Protein pI : 8.58
Protein Weight : 18091.15
Protein Length : 235
Protein Note : Flavivirus polyprotein propeptide; pfam01570

Protein Sequence : Show Sequence

>AAK71232.1 preM protein, partial [Japanese encephalitis virus]
MKLSNFQGKLLMTINNTDIADVIVIPTSKGENRCWVRAIDVGYMCEDTITYECPKLTMGNDPEDVDCWCD
NQEVYVQYGRCTRTRHSKRSRRSVSVQTHGESSLVNKKEAWLDSTKATRYLMKTENWIIRNPGYAFLAAA
LGWMLGSNNGQRVVFTILLLLVAPAYS

Molecule Role : Protective antigen
Molecule Role Annotation : A cDNA clone representing the genome of structural proteins of Japanese encephalitis virus (JEV) was inserted into the thymidine kinase gene of vaccinia virus strains LC16mO and WR. Inoculation of rabbits with the infectious recombinant vaccinia virus resulted in rapid production of antiserum specific for the PreM and E glycoproteins of JEV. Mice vaccinated with the recombinant produced JEV-neutralizing antibodies and were resistant to challenge with JEV (Yasuda et al., 1990).

10. premembrane protein

Gene Name : premembrane protein
Sequence Strain (Species/Organism) : Japanese encephalitis virus
NCBI Protein GI : ACI16478
Other Database IDs : CDD:279856
Taxonomy ID : 11072
Protein Name : premembrane protein
Protein pI : 3.95
Protein Weight : 8470.75
Protein Length : 154
Protein Note : genotype: 3

Protein Sequence : Show Sequence

>ACI16478.1 premembrane protein, partial [Japanese encephalitis virus]
VIACAGAMKLSNFQGKLLMTVNNTDIADVIVIPTSKGENRCWVRAIDVGYMCEDTITYECPKLTMGNDPE
DVDCWCDNQE

Molecule Role : Protective antigen
Molecule Role Annotation : (Qian et al., 2015)

11. PrM

Gene Name : PrM
Sequence Strain (Species/Organism) : Japanese encephalitis virus
VO ID : VO_0011146
NCBI Protein GI : 90019439
Other Database IDs : CDD:279856
Taxonomy ID : 11072
Gene Strand (Orientation) : ?
Protein Name : PrM
Protein pI : 4.01
Protein Weight : 8654.05
Protein Length : 138
Protein Note : Flavivirus polyprotein propeptide; pfam01570

Protein Sequence : Show Sequence

>ABD84370.1 PrM, partial [Japanese encephalitis virus]
VIACVGAMKLSNFQGKLLMTINKTDIADVIVIPTSKGENRCWVRAIDVGYMCEDTITYECPKLTMGNDPE
DVDCWCDNQE

Molecule Role : Protective antigen
Molecule Role Annotation : Researchers established a simple and effective method for DNA immunization against Japanese encephalitis virus (JEV) infection with plasmids encoding the viral PrM and E proteins and colloidal gold. After being inoculated twice, BALB/c mice were found to resist challenge with 100,000 times the 50% lethal dose (LD(50)) of JEV (Beijing-1 strain) even when immunized with a relatively small dose of 0.5 micro g of plasmid DNA (Zhao et al., 2003).
Related Vaccine(s): Japanese encephalitis virus DNA vaccine encoding E protein , Japanese encephalitis virus DNA vaccine encoding PrM , NYVAC-JEV- prM/E/ NS1

12. PrM from West Nile Virus

Gene Name : PrM from West Nile Virus
Sequence Strain (Species/Organism) : West Nile virus NY99
NCBI Protein GI : 158516890
Other Database IDs : CDD:110567
CDD:201546
VBRC:36388
Taxonomy ID : 11082
Gene Strand (Orientation) : ?
Protein Name : prM protein
Protein Length : 167
Protein Note : lineage 1; Vero cell passage 2 after isolation

Protein Sequence : Show Sequence

>gi|158516890|ref|YP_001527879.1| unnamed protein product [West Nile virus]
VTLSNFQGKVMMTVNATDVTDVITIPTAAGKNLCIVRAMDVGYMCDDTITYECPVLSAGNDPEDIDCWCT
KSAVYVRYGRCTKTRHSRRSRRSLTVQTHGESTLANKKGAWMDSTKATRYLVKTESWILRNPGYALVAAV
IGWMLGSNTMQRVVFVVLLLLVAPAYS

Molecule Role : Other

III. Vaccine Related Host Genes

1. Ifng (Interferon gamma)

Gene Name : Ifng (Interferon gamma)
Sequence Strain (Species/Organism) : Mouse
NCBI Gene ID : 15978
NCBI Protein GI : 33468859
Genbank Accession : NM_008337
Protein Accession : NP_032363.1
Other Database IDs : MGI:107656; UniProt: P01580
Taxonomy ID : 10090
Gene Strand (Orientation) : ?

DNA Sequence : Show Sequence

>gi|145966741|ref|NM_008337.3| Mus musculus interferon gamma (Ifng), mRNA
ATAGCTGCCATCGGCTGACCTAGAGAAGACACATCAGCTGATCCTTTGGACCCTCTGACTTGAGACAGAA
GTTCTGGGCTTCTCCTCCTGCGGCCTAGCTCTGAGACAATGAACGCTACACACTGCATCTTGGCTTTGCA
GCTCTTCCTCATGGCTGTTTCTGGCTGTTACTGCCACGGCACAGTCATTGAAAGCCTAGAAAGTCTGAAT
AACTATTTTAACTCAAGTGGCATAGATGTGGAAGAAAAGAGTCTCTTCTTGGATATCTGGAGGAACTGGC
AAAAGGATGGTGACATGAAAATCCTGCAGAGCCAGATTATCTCTTTCTACCTCAGACTCTTTGAAGTCTT
GAAAGACAATCAGGCCATCAGCAACAACATAAGCGTCATTGAATCACACCTGATTACTACCTTCTTCAGC
AACAGCAAGGCGAAAAAGGATGCATTCATGAGTATTGCCAAGTTTGAGGTCAACAACCCACAGGTCCAGC
GCCAAGCATTCAATGAGCTCATCCGAGTGGTCCACCAGCTGTTGCCGGAATCCAGCCTCAGGAAGCGGAA
AAGGAGTCGCTGCTGATTCGGGGTGGGGAAGAGATTGTCCCAATAAGAATAATTCTGCCAGCACTATTTG
AATTTTTAAATCTAAACCTATTTATTAATATTTAAAACTATTTATATGGAGAATCTATTTTAGATGCATC
AACCAAAGAAGTATTTATAGTAACAACTTATATGTGATAAGAGTGAATTCCTATTAATATATGTGTTATT
TATAATTTCTGTCTCCTCAACTATTTCTCTTTGACCAATTAATTATTCTTTCTGACTAATTAGCCAAGAC
TGTGATTGCGGGGTTGTATCTGGGGGTGGGGGACAGCCAAGCGGCTGACTGAACTCAGATTGTAGCTTGT
ACCTTTACTTCACTGACCAATAAGAAACATTCAGAGCTGCAGTGACCCCGGGAGGTGCTGCTGATGGGAG
GAGATGTCTACACTCCGGGCCAGCGCTTTAACAGCAGGCCAGACAGCACTCGAATGTGTCAGGTAGTAAC
AGGCTGTCCCTGAAAGAAAGCAGTGTCTCAAGAGACTTGACACCTGGTGCTTCCCTATACAGCTGAAAAC
TGTGACTACACCCGAATGACAAATAACTCGCTCATTTATAGTTTATCACTGTCTAATTGCATATGAATAA
AGTATACCTTTGCAACC

Protein Sequence : Show Sequence

>gi|33468859|ref|NP_032363.1| interferon gamma [Mus musculus]
MNATHCILALQLFLMAVSGCYCHGTVIESLESLNNYFNSSGIDVEEKSLFLDIWRNWQKDGDMKILQSQI
ISFYLRLFEVLKDNQAISNNISVIESHLITTFFSNSKAKKDAFMSIAKFEVNNPQVQRQAFNELIRVVHQ
LLPESSLRKRKRSRC

Molecule Role Annotation : IFN-gamma plays a critical role in Th1 type immune response. It is important for protection against infections by various viruses and intracellular bacteria.
Additional Molecule Role : Vaximmutor
Additional Molecule Role Annotation : The experimental data demonstrated that three time vaccinations with BCG in BALB/c mice induced strong TB Ag-specific IFN-gamma immune responses in splenocytes (Wang et al., 2009).
Related Vaccine(s): Japanese encephalitis virus vaccine BV-G-E

IV. Vaccine Information

1. ALVAC-JEV

a. Vaccine Ontology ID:

VO_0004777

b. Type:

Recombinant vector vaccine

c. Status:

Research

d. Host Species for Licensed Use:

Baboon

e. Preparation

Poxvirus-vectored vaccines for Japanese encephalitis (JE), NYVAC-JEV and ALVAC-JEV(Raengsakulrach et al., 1999).

f. Immunization Route

Intramuscular injection (i.m.)

g. Monkey Response

Vaccination Protocol: The vaccines were given to four monkeys each on study days 0 and 28 along with saline placebo on day 7. For controls, the licensed BIKEN JE vaccine and a saline placebo were given to other groups of four monkeys on days 0, 7, and 28 (Raengsakulrach et al., 1999).
Vaccine Immune Response Type: VO_0003057
Challenge Protocol: Two months after the booster dose, all 16 monkeys were challenged intranasally with one 90% effective dose of JEV strain KE-93 (AP61-1, C6/36-1, Mm-1, SM-2) (Raengsakulrach et al., 1999).
Efficacy: This study suggests that the NYVAC-JEV and ALVAC-JEV vaccines are safe and immunogenic in monkeys and that the NYVAC-JEV and BIKEN vaccines are effective in protecting monkeys from encephalitis (Raengsakulrach et al., 1999).

2. Ixiaro

a. Product Name:

Japanese Encephalitis Vaccine, Inactivated, Adsorbed

b. Tradename:

IXIARO

c. Manufacturer:

Valneva SE

d. Vaccine Ontology ID:

VO_0011558

e. CDC CVX code:

134

f. Type:

Inactivated or "killed" vaccine

g. Status:

Licensed

h. Location Licensed:

USA, Canada

i. Host Species for Licensed Use:

Human

j. Adjuvant:

VO ID: VO_0000127

k. Preparation

JEV strain SA14-14-2 is propagated in Vero cells, and harvested. The harvested virus suspension is treated with protamine sulfate to remove contaminating DNA and proteins and centrifuged. Virus is inactivated by formaldehyde and aluminum hydroxide is added Ref917:FDA: Ixiaro].

l. Immunization Route

Intramuscular injection (i.m.)

m. Storage

Store in a refrigerator at 2° to 8° C (35° to 46° F). Do not freeze.

n . Approved Age for Licensed Use

2 months of age and older

3. Japanese encephalitis virus (JEV)

a. Type:

Recombinant vector vaccine

b. Status:

Licensed

c. Host Species for Licensed Use:

Baboon

d. Immunization Route

Intramuscular injection (i.m.)

4. Japanese encephalitis virus DNA vaccine encoding E protein

a. Vaccine Ontology ID:

VO_0011353

b. Type:

DNA vaccine

c. Status:

Research

d. Antigen

Japanese encephalitis virus PrM and E protein

e. Gene Engineering of PrM

Type: DNA vaccine construction
Description: Plasmid pSLKJ12 contains the premembrane signal sequence as well as the premembrane (PrM) and envelope (E) genes of the Sagayama strain of JEV. The viral sequence, spanning nucleotides 408 to 2477, was retrieved from this plasmid by PstI-EcoRI digestion. The fragment was cloned into the eukaryotic expression vectors pcDL-SRα296 and pCAGGS, generously provided by Y. Takebe (Laboratory of Molecular Virology and Epidemiology, AIDS Research Center, National Institute of Infectious Diseases, Shinjuku-ku, Tokyo, Japan) and J. Miyazaki (Division of Stem Cell Regulation Research, G6, Osaka University Medical School, Suita, Osaka, Japan), respectively. They are purified and designated pSRαJ12 and pCAGJ12, respectively (Zhao et al., 2003).
Detailed Gene Information: Click here.

f. Gene Engineering of E

Type: DNA vaccine construction
Description: Plasmid pSLKJ12 contains the premembrane signal sequence as well as the premembrane (PrM) and envelope (E) genes of the Sagayama strain of JEV. The viral sequence, spanning nucleotides 408 to 2477, was retrieved from this plasmid by PstI-EcoRI digestion. The fragment was cloned into the eukaryotic expression vectors pcDL-SRα296 and pCAGGS, generously provided by Y. Takebe (Laboratory of Molecular Virology and Epidemiology, AIDS Research Center, National Institute of Infectious Diseases, Shinjuku-ku, Tokyo, Japan) and J. Miyazaki (Division of Stem Cell Regulation Research, G6, Osaka University Medical School, Suita, Osaka, Japan), respectively (Zhao et al., 2003).
Detailed Gene Information: Click here.

g. Vector:

Expression vectors pcDL-SRα296 and pCAGGS

h. Immunization Route

Intravenous injection (i.v.)

i. Mouse Response

Host Strain: BALB/c
Vaccination Protocol: For the protection test, 3-week-old female BALB/c mice were inoculated with either 50, 5, or 0.5 μg of the mixture on days 0 and 9 intravenously or intradermally (Zhao et al., 2003).
Challenge Protocol: On day 22, all immunized mice were challenged by an intraperitoneal injection of 100,000 times the LD50 of JEV (Beijing-1 strain, 0.15 ml), at which time they were simultaneously inoculated intracerebrally with 25 μl of saline into the right hemisphere of their brains with a 27-gauge one-stop needle (Top Injection Needle, Tokyo, Japan) (Zhao et al., 2003).
Efficacy: Researchers established a simple and effective method for DNA immunization against Japanese encephalitis virus (JEV) infection with plasmids encoding the viral PrM and E proteins and colloidal gold. After being inoculated twice, BALB/c mice were found to resist challenge with 100,000 times the 50% lethal dose (LD(50)) of JEV (Beijing-1 strain) even when immunized with a relatively small dose of 0.5 micro g of plasmid DNA (Zhao et al., 2003).

5. Japanese encephalitis virus DNA vaccine encoding NS1 (pUSK-NS1)

a. Vaccine Ontology ID:

VO_0011500

b. Type:

DNA vaccine

c. Status:

Research

d. Antigen

Japanese encephalitis virus NS1

e. Gene Engineering of NS1

Type: DNA vaccine construction
Description: NS1 gene of Japanese encephalitis virus (JEV) SA14-14-2 strain was produced by reverse transcriptase-mediated PCR (RT-PCR) and was cloned into vector pUSK to form recombinant plasmid (designed as pUSK-NS1) (Xu et al., 2004).
Detailed Gene Information: Click here.

f. Vector:

pUSK

g. Immunization Route

Intramuscular injection (i.m.)

h. Mouse Response

Host Strain: BALB/c
Vaccination Protocol: Ten 6-week-old Balb/c mice and eight 2-days old piglets were immunized with 5.0 log10pfu of the TK−/gG−/NS1+ mutant, while another equal number of animal in control groups with PBS (Xu et al., 2004).
Challenge Protocol: The challenge was performed with PRV Ea strain at a concentration of 6.5 log10pfu (LD50=10−4.5) at day 7 for mice and day 14 for piglets post-vaccination (Xu et al., 2004).
Efficacy: Balb/c mice and swine vaccinated with TK(-)/gG(-)/NS1(+) expressing NS1 protein of JEV could confer protective immunity against lethal challenge of the virulent PRV Ea strain and develop a good humoral and cellular immune response against JEV (Xu et al., 2004).

6. Japanese encephalitis virus DNA vaccine encoding PrM

a. Vaccine Ontology ID:

VO_0011345

b. Type:

DNA vaccine

c. Status:

Research

d. Antigen

envelope protein

e. Gene Engineering of PrM

Type: DNA vaccine construction
Description: Plasmid pSLKJ12 contains the premembrane signal sequence as well as the premembrane (PrM) and envelope (E) genes of the Sagayama strain of JEV. The viral sequence, spanning nucleotides 408 to 2477, was retrieved from this plasmid by PstI-EcoRI digestion. The fragment was cloned into the eukaryotic expression vectors pcDL-SRα296 and pCAGGS, generously provided by Y. Takebe (Laboratory of Molecular Virology and Epidemiology, AIDS Research Center, National Institute of Infectious Diseases, Shinjuku-ku, Tokyo, Japan) and J. Miyazaki (Division of Stem Cell Regulation Research, G6, Osaka University Medical School, Suita, Osaka, Japan), respectively. They are purified and designated pSRαJ12 and pCAGJ12, respectively (Zhao et al., 2003).
Detailed Gene Information: Click here.

f. Vector:

Expression vectors pcDL-SRα296 and pCAGGS

g. Immunization Route

Intravenous injection (i.v.)

h. Mouse Response

Host Strain: BALB/c
Vaccination Protocol: For the protection test, 3-week-old female BALB/c mice were inoculated with either 50, 5, or 0.5 μg of the mixture on days 0 and 9 intravenously or intradermally (Zhao et al., 2003).
Challenge Protocol: On day 22, all immunized mice were challenged by an intraperitoneal injection of 100,000 times the LD50 of JEV (Beijing-1 strain, 0.15 ml), at which time they were simultaneously inoculated intracerebrally with 25 μl of saline into the right hemisphere of their brains with a 27-gauge one-stop needle (Top Injection Needle, Tokyo, Japan) (Zhao et al., 2003).
Efficacy: Researchers established a simple and effective method for DNA immunization against Japanese encephalitis virus (JEV) infection with plasmids encoding the viral PrM and E proteins and colloidal gold. After being inoculated twice, BALB/c mice were found to resist challenge with 100,000 times the 50% lethal dose (LD(50)) of JEV (Beijing-1 strain) even when immunized with a relatively small dose of 0.5 micro g of plasmid DNA (Zhao et al., 2003).

7. Japanese encephalitis virus DNA Vaccine P-JEV

a. Vaccine Ontology ID:

VO_0004586

b. Type:

DNA vaccine

c. Status:

Research

d. Gene Engineering of E

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

e. Gene Engineering of NS1

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

f. Gene Engineering of M protein

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

g. Vector:

pcDNA3.1/V5-His-P-JEV (Kulkarni et al., 2012)

h. Immunization Route

Intramuscular injection (i.m.)

i. Mouse Response

Vaccination Protocol: Control mice received 1 μg of pcDNA3.1/V5-His plasmid per dose. While same amount of recombinant plasmid, pcDNA3.1/V5-His-P-JEV was used to immunize the experimental group. Groups of BALB/c mice (n = 10), received two booster doses with equal amount of DNA after every 2 weeks (Kulkarni et al., 2012).
Vaccine Immune Response Type: VO_0003057
Immune Response: Anti-JEV antibodies were detectable in all mouse groups 31 days after immunization. Levels of these antibodies increased after the first booster immunization and were further enhanced after the second booster dose. Following the challenge, pcDNA3.1/V5-His-P-JEV immunized mice showed significantly enhanced JEV antibody titres (Kulkarni et al., 2012).
Challenge Protocol: At 6 weeks after immunization, mice were challenged with lethal dose of 100LD50 with JEV 733913 strain by intraperitonial route, followed by 1% starch by the intracerebral route to breach the blood brain barrier (Kulkarni et al., 2012).
Efficacy: Approximately 83% of mice immunized with the vaccine survived the challenge injection (Kulkarni et al., 2012).

8. Japanese encephalitis virus DNA Vaccine pCJ-3/E encoding E

a. Vaccine Ontology ID:

VO_0004587

b. Type:

DNA vaccine

c. Status:

Research

d. Gene Engineering of E

Type: DNA vaccine construction
Description:
Detailed Gene Information: Click here.

e. Vector:

pCJ-3/E (Wu et al., 2006)

f. Immunization Route

Intramuscular injection (i.m.)

g. Mouse Response

Vaccination Protocol: All mice were immunized intramuscularly at 6 to 8 weeks of age. Groups of five mice were anesthetized and injected three times at 3-week intervals with 100 μg of DNA (Wu et al., 2006).
Vaccine Immune Response Type: VO_0003057
Immune Response: The vaccine enhanced the production of higher titers of neutralizing antibodies, and generated both cellular and humoral immunity (Wu et al., 2006).
Challenge Protocol: For a lethal challenge experiment, C3H/HeN mice were injected intraperitoneally with 50 times the LD50 of JEV Beijing-1 and intracerebrally with PBS (Wu et al., 2006).
Efficacy: In terms of survival rates of immunized mice challenged with JEV virus at week 16, 100% protection was seen with pCJ-3/E-immunized mice (Wu et al., 2006).

9. Japanese encephalitis virus DNA vaccine pUJENS3

a. Vaccine Ontology ID:

VO_0011501

b. Type:

DNA vaccine

c. Status:

Research

d. Antigen

Japanese encephalitis virus non-structural protein NS3

e. Gene Engineering of NS3

Type: DNA vaccine construction
Description: Amplified DNA fragments containing the NS3 gene was ligated to the pUBIQ vector at the EcoRI/XbaI site to construct pUJENS3 (Konishi et al., 2003).
Detailed Gene Information: Click here.

f. Vector:

pUBIQ vector

g. Immunization Route

Intramuscular injection (i.m.)

h. Mouse Response

Host Strain: BALB/c
Vaccination Protocol: Four-to-six-week-old male BALB/c mice were immunized intramuscularly (i.m.) with 100 μg of plasmid DNA one to three times at intervals of 2 weeks. For evaluation of CTL induction, spleens were collected from groups of two immunized mice 2–4 weeks after the last immunization (Konishi et al., 2003).
Challenge Protocol: For evaluation of protective efficacy, groups of 6–12 immunized mice were bled retroorbitally for evaluating pre-challenge serum neutralizing antibody titers, and then challenged i.p. with 100 or 400 LD50 of the P3 strain of JE virus, 6 weeks after the first immunization. Mice were observed for 21 days, and surviving mice were bled for evaluating post-challenge serum neutralizing antibody titers. For monitoring virus load following challenge, groups of 18 immunized mice were challenged with 100 LD50 of the P3 strain, and 600–700 μl of blood and the whole brain were collected 1 h (day 0) or consecutive 5 days (days 1–5) following challenge from 3 mice per day per group (Konishi et al., 2003).
Efficacy: Researchers constructed plasmid DNAs encoding JE virus proteins. Cytotoxic T lymphocytes (CTLs) were induced by NS3 in a mouse model. Three immunizations with pUJENS3 provided a 50% partial protection from a lethal dose of JE virus (Konishi et al., 2003).

10. Japanese encephalitis virus DNA vaccine pUJENS5

a. Vaccine Ontology ID:

VO_0011352

b. Type:

DNA vaccine

c. Status:

Research

d. Antigen

Japanese encephalitis virus NS5

e. Gene Engineering of NS5

Type: DNA vaccine construction
Description: Amplified DNA fragments containing the NS5 gene was ligated to the pUBIQ8 vector at the BspEI and/or XbaI sites to construct pUJENS5 (Konishi et al., 2003).
Detailed Gene Information: Click here.

f. Vector:

pUBIQ vector

g. Immunization Route

Intramuscular injection (i.m.)

h. Mouse Response

Host Strain: BALB/c
Vaccination Protocol: Four-to-six-week-old male BALB/c mice were immunized intramuscularly (i.m.) with 100 μg of plasmid DNA one to three times at intervals of 2 weeks. For evaluation of CTL induction, spleens were collected from groups of two immunized mice 2–4 weeks after the last immunization (Konishi et al., 2003).
Challenge Protocol: For evaluation of protective efficacy, groups of 6–12 immunized mice were bled retroorbitally for evaluating pre-challenge serum neutralizing antibody titers, and then challenged i.p. with 100 or 400 LD50 of the P3 strain of JE virus, 6 weeks after the first immunization. Mice were observed for 21 days, and surviving mice were bled for evaluating post-challenge serum neutralizing antibody titers. For monitoring virus load following challenge, groups of 18 immunized mice were challenged with 100 LD50 of the P3 strain, and 600–700 μl of blood and the whole brain were collected 1 h (day 0) or consecutive 5 days (days 1–5) following challenge from 3 mice per day per group (Konishi et al., 2003).
Efficacy: Researchers constructed plasmid DNAs encoding JE virus proteins. Cytotoxic T lymphocytes (CTLs) were induced by NS5 in a mouse model. Three immunizations with pUJENS5 provided a 57% partial protection from a lethal dose of JE virus (Konishi et al., 2003).

11. Japanese encephalitis virus vaccine BV-G-E

a. Vaccine Ontology ID:

VO_0011516

b. Type:

Recombinant vector vaccine

c. Status:

Research

d. Antigen

Japanese encephalitis virus envelope protein

e. Gene Engineering of E

Type: Recombinant vector construction
Description: Recombinant pseudotype baculovirus (BV-G-E) was generated by inserting JEV E gene fragment into pFastBac-VSV/G vector. BALB/c mice were immunized with BV-G-E and challenged with JEV wild-type strain. The neutralization antibody, interferon (IFN)- expression and release, and survival rate were analysed and compared with the group of immunized with inactivated vaccine and DNA vaccine (pc-E) encoding the same gene of JEV (Li et al., 2009).
Detailed Gene Information: Click here.

f. Vector:

baculovirus pseudotyped with vesicular stomatitis virus glycoprotein (VSVG)

g. Immunization Route

Intramuscular injection (i.m.)

h. Mouse Response

Host Strain: BALB/c
Vaccination Protocol: Four-week old female BALB/c mice (purchased from the Animal Centre, Institute of Medicine (Hubei Province, China) were randomly divided into seven groups (15 mice per group). Three groups were injected intramuscularly (i.m.) with 100 µl of PBS containing 1 × 10^8, 1 × 10^9 and 1 × 10^10 PFU of BV-G-E, respectively. The other three groups were injected intramuscularly with 100 µl of PBS containing 1 × 10^10 PFU of BV-G-EGFP or 100 µg of pc-E (a DNA vaccine construct expressing E protein) or 100 µl inactivated vaccine. The last group was used as a negative control by intramuscularly injecting 100 µl of PBS. Booster immunizations were identically performed 3 weeks later (Li et al., 2009).
Challenge Protocol: A subset of immunized mice was intraperitoneally (i.p.) challenged with 105 PFU of wild-type JEV P3 in 0.1 ml at 6 weeks following the initial immunization. Mouse mortality was monitored daily for 3 weeks (Li et al., 2009).
Efficacy: Researchers constructed a recombinant pseudotype baculovirus encoding the JEV envelope (E) protein and demonstrated that it could elicit high protective immunity in mice. Intramuscular injections of BV-G-E at various doses into mice produced higher levels of JEV-specific neutralizing antibodies, IFN-gamma and better protective efficacy against a lethal challenge with JEV than that of pc-E. Furthermore, BV-G-E could elicit a higher level of cellular immunity response and provide equal protective efficacy against JEV challenge compared to inactivated vaccine (Li et al., 2009).
Host Gene Response of Ifng (Interferon gamma)
- Gene Response: An evident dose-dependent pattern of IFN-gamma production could be observed in mice immunized with BV-G-E. As expected, no significant production of IFN-γ was detected in PBS-inoculated mice. Interestingly, the mean relative IFN-γ mRNA expression in the group of BV-G-EGFP was also significantly higher than that of pc-E vaccinated mice in splenocytes (Li et al., 2009).
- Detailed Gene Information: Click here.

12. NYVAC-JEV

a. Vaccine Ontology ID:

VO_0004776

b. Type:

Recombinant vector vaccine

c. Status:

Research

d. Host Species for Licensed Use:

Baboon

e. Preparation

Poxvirus-vectored vaccines for Japanese encephalitis (JE), NYVAC-JEV and ALVAC-JEV(Raengsakulrach et al., 1999).

f. Immunization Route

Intramuscular injection (i.m.)

g. Monkey Response

Vaccination Protocol: The vaccines were given to four monkeys each on study days 0 and 28 along with saline placebo on day 7. For controls, the licensed BIKEN JE vaccine and a saline placebo were given to other groups of four monkeys on days 0, 7, and 28 (Raengsakulrach et al., 1999).
Vaccine Immune Response Type: VO_0003057
Challenge Protocol: Two months after the booster dose, all 16 monkeys were challenged intranasally with one 90% effective dose of JEV strain KE-93 (AP61-1, C6/36-1, Mm-1, SM-2) (Raengsakulrach et al., 1999).
Efficacy: This study suggests that the NYVAC-JEV and ALVAC-JEV vaccines are safe and immunogenic in monkeys and that the NYVAC-JEV and BIKEN vaccines are effective in protecting monkeys from encephalitis (Raengsakulrach et al., 1999).

13. NYVAC-JEV- prM/E/ NS1

a. Vaccine Ontology ID:

VO_0004780

b. Type:

Recombinant vector vaccine

c. Status:

Research

d. Host Species for Licensed Use:

Baboon

e. Gene Engineering of PrM

Type: Recombinant vector construction
Description: A highly attenuated strain of vaccinia virus (NYVAC) was engineered to express the Japanese encephalitis virus (JEV) prM, E, and NS1 genes or the prM and E genes (Konishi et al., 1992).
Detailed Gene Information: Click here.

f. Gene Engineering of NS1

Type: Recombinant vector construction
Description: A highly attenuated strain of vaccinia virus (NYVAC) was engineered to express the Japanese encephalitis virus (JEV) prM, E, and NS1 genes or the prM and E genes (Konishi et al., 1992).
Detailed Gene Information: Click here.

g. Gene Engineering of E

Type: Recombinant protein preparation
Description: A highly attenuated strain of vaccinia virus (NYVAC) was engineered to express the Japanese encephalitis virus (JEV) prM, E, and NS1 genes or the prM and E genes (Konishi et al., 1992).
Detailed Gene Information: Click here.

h. Preparation

Highly attenuated strain of vaccinia virus (NYVAC) was engineered to express the Japanese encephalitis virus (JEV) prM, E, and NS1 genes or the prM and E genes (Konishi et al., 1992).

i. Immunization Route

Intramuscular injection (i.m.)

j. Pig Response

Vaccination Protocol: The recombinant viruses were tested as vaccine candidates in pigs, a natural host of JEV. JEV-neutralizing and hemagglutination-inhibiting antibodies appeared in swine sera 7 days after immunization with 108 PFU of the recombinant viruses and increased after a second dose at 28 days (Konishi et al., 1992).
Vaccine Immune Response Type: VO_0003057
Challenge Protocol: JEV challenge (d56) of the swine with 2 × 10^8 PFU of JEV (Konishi et al., 1992).
Efficacy: The JEV levels detected in the serum after JEV challenge were significantly reduced in animals inoculated with the recombinant viruses (Konishi et al., 1992).

V. References

1. FDA: Ixiaro: FDA: Ixiaro [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm179132.htm]

2. FDA: JE-Vax: FDA: JE-Vax vaccine information [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094048.htm]

3. Hua et al., 2014: Hua RH, Liu LK, Huo H, Li YN, Guo LP, Wang XL, Qin CF, Bu ZG. Comprehensive mapping of a novel NS1 epitope conserved in flaviviruses within the Japanese encephalitis virus serocomplex. Virus research. 2014; 185; 103-109. [PubMed: 24631788].

4. Konishi et al., 1992: Konishi E, Pincus S, Paoletti E, Laegreid WW, Shope RE, Mason PW. A highly attenuated host range-restricted vaccinia virus strain, NYVAC, encoding the prM, E, and NS1 genes of Japanese encephalitis virus prevents JEV viremia in swine. Virology. 1992; 190(1); 454-458. [PubMed: 1326813].

5. Konishi et al., 2003: Konishi E, Ajiro N, Nukuzuma C, Mason PW, Kurane I. Comparison of protective efficacies of plasmid DNAs encoding Japanese encephalitis virus proteins that induce neutralizing antibody or cytotoxic T lymphocytes in mice. Vaccine. 2003; 21(25-26); 3675-3683. [PubMed: 12922097].

6. Kulkarni et al., 2012: Kulkarni R, Sapkal G, Gore M. Evaluation of Japanese encephalitis virus polytope DNA vaccine candidate in BALB/c mice. Virus research. 2012; 170(1-2); 118-125. [PubMed: 23007095].

7. Li et al., 2009: Li Y, Ye J, Cao S, Xiao S, Zhao Q, Liu X, Jin M, Chen H. Immunization with pseudotype baculovirus expressing envelope protein of Japanese encephalitis virus elicits protective immunity in mice. The journal of gene medicine. 2009; 11(1); 57-65. [PubMed: 19006097].

8. Qian et al., 2015: Qian P, Zhi X, Wang B, Zhang H, Chen H, Li X. Construction and immune efficacy of recombinant pseudorabies virus expressing PrM-E proteins of Japanese encephalitis virus genotype ?. Virology journal. 2015; 12; 214. [PubMed: 26651827].

9. Raengsakulrach et al., 1999: Raengsakulrach B, Nisalak A, Gettayacamin M, Thirawuth V, Young GD, Myint KS, Ferguson LM, Hoke CH Jr, Innis BL, Vaughn DW. Safety, immunogenicity, and protective efficacy of NYVAC-JEV and ALVAC-JEV recombinant Japanese encephalitis vaccines in rhesus monkeys. The American journal of tropical medicine and hygiene. 1999; 60(3); 343-349. [PubMed: 10466959].

10. Sheets et al., 2006: Sheets RL, Stein J, Manetz TS, Duffy C, Nason M, Andrews C, Kong WP, Nabel GJ, Gomez PL. Biodistribution of DNA plasmid vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile virus is similar, without integration, despite differing plasmid backbones or gene inserts. Toxicological sciences : an official journal of the Society of Toxicology. 2006; 91(2); 610-619. [PubMed: 16569729].

11. Wiki: Japanese encephalitis: Wiki: Japanese encephalitis [http://en.wikipedia.org/wiki/Japanese_encephalitis]

12. Wu et al., 2006: Wu CJ, Li TL, Huang HW, Tao MH, Chan YL. Development of an effective Japanese encephalitis virus-specific DNA vaccine. Microbes and infection / Institut Pasteur. 2006; 8(11); 2578-2586. [PubMed: 16949850].

13. Xu et al., 2004: Xu G, Xu X, Li Z, He Q, Wu B, Sun S, Chen H. Construction of recombinant pseudorabies virus expressing NS1 protein of Japanese encephalitis (SA14-14-2) virus and its safety and immunogenicity. Vaccine. 2004; 22(15-16); 1846-1853. [PubMed: 15121294].

14. Yasuda et al., 1990: Yasuda A, Kimura-Kuroda J, Ogimoto M, Miyamoto M, Sata T, Sato T, Takamura C, Kurata T, Kojima A, Yasui K. Induction of protective immunity in animals vaccinated with recombinant vaccinia viruses that express PreM and E glycoproteins of Japanese encephalitis virus. Journal of virology. 1990; 64(6); 2788-2795. [PubMed: 2159544].

15. Zhao et al., 2003: Zhao Z, Wakita T, Yasui K. Inoculation of plasmids encoding Japanese encephalitis virus PrM-E proteins with colloidal gold elicits a protective immune response in BALB/c mice. Journal of virology. 2003; 77(7); 4248-4260. [PubMed: 12634382].